Jacobs Levy Equity Management’s MacroGenics MGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.27M | Sell |
441,143
-459,914
| -51% | -$981K | 0.01% | 666 |
|
|
2025
Q4 | $1.45M | Buy |
901,057
+85,192
| +10% | +$134K | 0.01% | 632 |
|
|
2025
Q3 | $1.37M | Sell |
815,865
-188,933
| -19% | -$306K | 0.01% | 661 |
|
|
2025
Q2 | $1.22M | Buy |
1,004,798
+339,447
| +51% | +$492K | ﹤0.01% | 721 |
|
|
2025
Q1 | $845K | Buy |
665,351
+99,447
| +18% | +$260K | ﹤0.01% | 843 |
|
|
2024
Q4 | $1.84M | Sell |
565,904
-424
| -0.1% | -$1.53K | 0.01% | 605 |
|
|
2024
Q3 | $1.86M | Buy |
566,328
+147,438
| +35% | +$574K | 0.01% | 619 |
|
|
2024
Q2 | $1.78M | Buy |
418,890
+270,872
| +183% | +$2.64M | 0.01% | 624 |
|
|
2024
Q1 | $2.18M | Buy |
148,018
+33,039
| +29% | +$499K | 0.01% | 580 |
|
|
2023
Q4 | $1.11M | Sell |
114,979
-284,505
| -71% | -$1.97M | 0.01% | 698 |
|
|
2023
Q3 | $1.86M | Sell |
399,484
-5,502
| -1% | -$27.4K | 0.01% | 570 |
|
|
2023
Q2 | $2.17M | Buy |
404,986
+100,864
| +33% | +$622K | 0.01% | 547 |
|
|
2023
Q1 | $2.18M | Buy |
304,122
+248,386
| +446% | +$1.5M | 0.01% | 557 |
|
|
2022
Q4 | $374K | Buy |
+55,736
| New | +$306K | ﹤0.01% | 834 |
|
|
2022
Q3 | – | Sell |
-71,224
| Closed | -$210K | – | 1107 |
|
|
2022
Q2 | $210K | Sell |
71,224
-97,000
| -58% | -$510K | ﹤0.01% | 955 |
|
|
2022
Q1 | $1.48M | Buy |
+168,224
| New | +$1.86M | 0.01% | 683 |
|
|
2020
Q4 | – | Sell |
-18,484
| Closed | -$466K | – | 1064 |
|
|
2020
Q3 | $466K | Sell |
18,484
-192,152
| -91% | -$5.25M | ﹤0.01% | 807 |
|
|
2020
Q2 | $5.88M | Sell |
210,636
-11,809
| -5% | -$205K | 0.06% | 305 |
|
|
2020
Q1 | $1.29M | Buy |
+222,445
| New | +$2.02M | 0.02% | 572 |
|
|
2019
Q2 | – | Sell |
-34,300
| Closed | -$617K | – | 995 |
|
|
2019
Q1 | $617K | Sell |
34,300
-108,566
| -76% | -$1.88M | 0.01% | 749 |
|
|
2018
Q4 | $1.81M | Buy |
142,866
+5,000
| +4% | +$83.9K | 0.03% | 476 |
|
|
2018
Q3 | $2.96M | Sell |
137,866
-11,304
| -8% | -$241K | 0.04% | 430 |
|
|
2018
Q2 | $3.08M | Buy |
149,170
+28,273
| +23% | +$637K | 0.05% | 409 |
|
|
2018
Q1 | $3.04M | Sell |
120,897
-27,139
| -18% | -$659K | 0.05% | 387 |
|
|
2017
Q4 | $2.81M | Buy |
148,036
+74,485
| +101% | +$1.39M | 0.05% | 392 |
|
|
2017
Q3 | $1.36M | Buy |
73,551
+54,161
| +279% | +$938K | 0.03% | 524 |
|
|
2017
Q2 | $340K | Sell |
19,390
-86,060
| -82% | -$1.64M | 0.01% | 755 |
|
|
2017
Q1 | $1.96M | Buy |
105,450
+84,250
| +397% | +$1.63M | 0.04% | 430 |
|
|
2016
Q4 | $433K | Buy |
+21,200
| New | +$534K | 0.01% | 705 |
|
|
2016
Q3 | – | Sell |
-53,817
| Closed | -$1.45M | – | 1087 |
|
|
2016
Q2 | $1.45M | Sell |
53,817
-29,140
| -35% | -$657K | 0.03% | 489 |
|
|
2016
Q1 | $1.55M | Buy |
+82,957
| New | +$1.58M | 0.03% | 467 |
|
Other funds holding MGNX
AC
VCM
RCM
WA
Jacobs Levy Equity Management's MGNX Position: Q1 2026 in Review
Jacobs Levy Equity Management reduced its MacroGenics (MGNX) stake by 51% in Q1 2026, selling an estimated $981K and leaving 441,143 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #666.
Jacobs Levy Equity Management first reported a position in MGNX in Q1 2016 and has held it in 31 quarters since. The position peaked at $5.88M in Q2 2020. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.
- Jacobs Levy Equity Management held 441,143 shares of MacroGenics worth $1.27M as of Q1 2026.
- Jacobs Levy Equity Management sold 459,914 MacroGenics shares in Q1 2026, an estimated $981K.
- MacroGenics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #666 holding.
- Jacobs Levy Equity Management first reported a position in MacroGenics in Q1 2016 and has held it in 31 quarters since.
- Jacobs Levy Equity Management's MacroGenics position peaked at $5.88M in Q2 2020.
- 109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.